HBeAg

Drug Farm Announces anti-HBV immunomodulator, DF-006 is Accepted as a Late-Breaking Presentation at the 2024 European Association for the Study of the Liver Conference

Retrieved on: 
Thursday, May 2, 2024
Research, Infectious Diseases, Genetics, Clinical Trials, Cardiology, Biotechnology, Pharmaceutical, Health, Optical, Science, University, EASL, Auckland City Hospital, HBeAg, Safety, Hepatitis, Intelligence, CccDNA, Patient, CHB, Immune system, Infection, HBV, ALPK1

Title: A phase 1, double-blinded, randomized, placebo-controlled, multicenter global study evaluating the safety, tolerability, and antiviral activity of DF-006 in chronic hepatitis B, virologically-suppressed patients.

Key Points: 
  • Title: A phase 1, double-blinded, randomized, placebo-controlled, multicenter global study evaluating the safety, tolerability, and antiviral activity of DF-006 in chronic hepatitis B, virologically-suppressed patients.
  • DF-006 is a first-in-class, orally administered ALPK1 agonist immunomodulator that potently stimulates local, innate immunity in the liver1.
  • DF-006 has a novel mechanism of action that is capable of stimulating the body’s own immune system to help clear the infection.
  • “DF-006 has demonstrated potent antiviral responses in preclinical studies, including inhibition of cccDNA and recruitment of T-cells.

Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)

Retrieved on: 
Thursday, December 7, 2023
Liver, AASLD, Multiple, NASH, SHBG, HBV, MBA, SAN, Therapy, Thyroid, THR, Doctor of Philosophy, HBeAg, CccDNA, Safety, Patient, Pharmacology, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, delivered oral presentations of clinical data for its capsid assembly modulator-empty (CAM-E), ALG-000184, and its thyroid hormone receptor-beta (THR-β) drug candidate, ALG-055009, at the Hep-DART 2023 meeting, held in Cabo San Lucas, Mexico, from December 3 – 7, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, delivered oral presentations of clinical data for its capsid assembly modulator-empty (CAM-E), ALG-000184, and its thyroid hormone receptor-beta (THR-β) drug candidate, ALG-055009, at the Hep-DART 2023 meeting, held in Cabo San Lucas, Mexico, from December 3 – 7, 2023.
  • The presentations can be found on the “Scientific Presentations & Conferences” section of the Aligos website ( www.aligos.com ).
  • “We’re greatly encouraged by the substantial and consistent reductions in HBV viral markers observed during prolonged dosing of ALG-000184 and are grateful for the opportunity to share these results with the scientific community at the Hep-DART 2023 meeting,” said Lawrence Blatt, Ph.D., MBA, Chairman & CEO of Aligos Therapeutics.
  • As presented at AASLD, ALG-055009 appears to have best-in-class potential.

Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)

Retrieved on: 
Friday, November 10, 2023
Hepatology, Safety, DNA, SAN, Therapy, PEI, HBsAg, AASLD, Emory University, Liver, Week, Doctor of Philosophy, B, CccDNA, Liver cancer, Hepatitis B virus, CHB, Entecavir, MBA, University, Hepatitis, Hong Kong, Physician, Poster, ETV, RNA, Vaccine, Pharmaceutical industry, HBeAg, Boston, New York University, Gastroenterology, Jacob Aligo

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that emerging hepatitis B antigen lowering data for its capsid assembly modulator – empty (CAM-E) drug, ALG-000184, are available as a late breaking poster at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), being held in Boston, Massachusetts, November 10 – 14, 2023.

Key Points: 
  • The data will be presented by Dr. Man-Fung Yuen, Chair and Professor of Gastroenterology and Hepatology at the University of Hong Kong, in Poster Hall C on Monday November 13 from 1-2 pm ET.
  • “ALG-000184 appears to have best-in-class antiviral properties which are also unique compared to other drug classes being evaluated for the treatment of chronic hepatitis B (CHB).
  • If the trends observed to date continue, ALG-000184 has the potential to become a cornerstone therapy in the treatment of CHB.
  • The antiviral effects of ALG-000184 presented at AASLD indicate that this drug is achieving significant viral suppression, likely via inhibition of cccDNA synthesis.

Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023

Retrieved on: 
Monday, November 13, 2023
Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Webcast, ID, Safety, DNA, Gene editing, Entrepreneurship, HBsAg, AASLD, IND, HBeAg, HBV, Conference call, Liver, CccDNA, Conference, CHB, Hepatitis, CTA, Precision BioSciences, Vaccine, Broadcasting, Boston

The poster highlights preclinical data demonstrating PBGENE-HBV’s ability to eliminate cccDNA and inactivate hepatitis B virus (HBV) DNA, meriting further investigation as a potentially curative treatment for chronic hepatitis B (CHB).

Key Points: 
  • The poster highlights preclinical data demonstrating PBGENE-HBV’s ability to eliminate cccDNA and inactivate hepatitis B virus (HBV) DNA, meriting further investigation as a potentially curative treatment for chronic hepatitis B (CHB).
  • The final clinical candidate nuclease demonstrated no detectable off-target editing at doses that maximized on-target editing.
  • In multiple HBV disease models, PBGENE-HBV demonstrated ability to inhibit viral markers and eliminate cccDNA in HBV-infected primary human liver cells.
  • These data are further supported by a high level of viral engagement and a 95% reduction in hepatitis B surface antigen (HBsAg) in an episomal HBV mouse model.

Aligos Therapeutics To Present Late Breaking Poster on ALG-000184, its CAM-E Drug Candidate, at The Liver Meeting® 2023

Retrieved on: 
Wednesday, October 25, 2023
American Association for the Study of Liver Diseases, Therapy, Hepatology, RNA, HBeAg, Liver, Poster, AASLD, University, MF, HBsAg, Liver disease, Hong Kong, SAN, DNA, Pharmaceutical industry, Vaccine, Gastroenterology

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that an abstract for its capsid assembly modulator – empty (CAM-E) drug candidate, ALG-000184, has been accepted as a late breaking poster at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), in Boston, Massachusetts, November 10 – 14, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that an abstract for its capsid assembly modulator – empty (CAM-E) drug candidate, ALG-000184, has been accepted as a late breaking poster at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), in Boston, Massachusetts, November 10 – 14, 2023.
  • The poster (#5028-C), titled “Long-term dosing with the capsid assembly modulator ALG-000184 results in multi-log reductions of DNA, RNA, HBsAg, HBeAg, and HBcrAg in untreated HBeAg positive chronic hepatitis B subjects,” will be presented in Poster Hall C on Monday, November 13 from 1-2 pm ET.
  • The presenting author is Dr. Man-Fung (MF) Yuen, Chair and Professor of Gastroenterology and Hepatology at the University of Hong Kong.

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 3, 2023
Database, DNA, Hou, EASL, Partnership, Therapy, NASH, Doctor of Philosophy, HBeAg, Janssen, CHB, MBA, RNA, HBsAg, Investment, SAN, Liver, R, ETV, Research, Pharmaceutical industry, Generic drug, Vaccine, Cryptocurrency, G&A

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the second quarter 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the second quarter 2023.
  • “We continue to make important progress in advancing our portfolio of drug candidates,” said Lawrence Blatt, Ph.D., MBA, Chairman & CEO of Aligos Therapeutics.
  • On July 31, 2023, Aligos Therapeutics, Inc. (the “Company”) and Janssen Biopharma, LLC (“Janssen”) filed a stipulation staying the case in their ongoing legal proceedings.
  • Cash, cash equivalents and investments totaled $90.8 million as of June 30, 2023, compared with $125.8 million as of December 31, 2022.

Best Presentation Award at EASL Congress 2023: First-in-class Bispecific Antibodies Anti-HBs×CD3 and Anti-HBs×CD28 Showed Strong Preclinical Efficacy in HBV Cure

Retrieved on: 
Wednesday, July 12, 2023
EASL, Human, POC, Leibniz-Institute of Virology, Vaccination, CD3, CD28, Serum, HBeAg, University Medical Center, Institute of technology, Infection, Technical University of Munich, University Medical Center Hamburg-Eppendorf, Antibody, SCG, Hepatocyte, Liver cancer, Hepatitis B, HBsAg, Death, Cancer, Liver, Infant, CccDNA, Lymphocyte, HBV, Vaccine, Virology

A combination of anti-HBs×CD3 and anti-HBs×CD28 activated human lymphocytes in HBV-infected human liver chimeric mice and demonstrated potent in vivo antiviral efficacy.

Key Points: 
  • A combination of anti-HBs×CD3 and anti-HBs×CD28 activated human lymphocytes in HBV-infected human liver chimeric mice and demonstrated potent in vivo antiviral efficacy.
  • Levels of HBV pgRNA, HBV DNA, and cccDNA in the liver dropped significantly, consistent with the decrease of HBV serum parameters, indicating efficient clearance of infected hepatocytes.
  • One in three humans experiences an HBV infection during their lifetime, and almost 300 million people are chronically infected worldwide.
  • Approximately 25% of chronic HBV infections progress to liver cancer, and HBV contributes to an estimated 820,000 deaths annually.

Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023

Retrieved on: 
Wednesday, June 21, 2023
PK, Asos, DNA, Conference, EASL, SSO, Modulation, Therapy, Doctor of Philosophy, Liver disease, Serum, HBeAg, Safety, Pharmacokinetics, CHB, MBA, RNA, NAP, AAV, Hepatocyte, Small RNA, Congress, Patient, Mouse, European Association for the Study of the Liver, ETV, PD-1, HBV, Hepatitis, State Police Services, Vaccine, Pharmaceutical industry, Palladium, Liver, HBsAg

SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that the company is presenting several posters collectively highlighting data from its liver disease programs at the European Association for the Study of the Liver (EASL) Congress 2023, taking place in Vienna, Austria, June 21 – 24, 2023.

Key Points: 
  • Notably, the Company’s late breaking poster (LBP-18) highlights promising emerging data from its ongoing Phase 1b study evaluating the oral capsid assembly modulator (CAM-E), ALG-000184.
  • Importantly, ALG-000184 continues to demonstrate a favorable safety and pharmacokinetic (PK) profile over these extended dosing durations.
  • “We are excited to present emerging clinical data from our CHB portfolio of drug candidates at EASL,” said Lawrence Blatt, Ph.D., MBA, Chairman & CEO of Aligos Therapeutics.
  • “The data presented highlights the progress we have made advancing new targeted therapies for multiple liver diseases.

Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023

Retrieved on: 
Wednesday, June 21, 2023
EASL, Therapy, Virology, HBeAg, NA, Clinical trial, Viral, CFBV, Congress, HBsAg, Patient, Clutch (eggs), RNA interference, European Association for the Study of the Liver, Safety, Pharmaceutical industry, Vaccine, Liver, Arbutus

WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that preliminary data from its on-going Phase 2a clinical trial evaluating the safety, tolerability and antiviral activity of the combination of AB-729, the Company’s lead RNAi therapeutic, and pegylated interferon alfa-2a (IFN) in patients with chronic hepatitis B virus (cHBV) was presented today at the European Association for the Study of the Liver (EASL) Congress. The preliminary data suggests that the addition of IFN to AB-729 treatment was generally well tolerated and appears to result in continued HBsAg declines in some patients.

Key Points: 
  • The preliminary data suggests that the addition of IFN to AB-729 treatment was generally well tolerated and appears to result in continued HBsAg declines in some patients.
  • William Collier, President and Chief Executive Officer of Arbutus, commented, “These data continue to support our strategy of utilizing AB-729 as a cornerstone in a combination therapeutic for patients with cHBV.
  • HBsAg levels
  • Three patients have been evaluated to stop NA treatment to date, with one meeting the protocol-defined criteria to stop NA treatment.

Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023

Retrieved on: 
Thursday, April 27, 2023
Flare, University of Hong Kong, Therapy, Virology, Cohort, Department of Medicine – University of Pamplona, NA, Clinical trial, Viral, CFBV, RNA, Antibody, AASLD, Hepatology, Patient, Division, University, Immune system, ALT, RNA interference, HBV, Vaccine, Pharmaceutical industry, HBeAg, HBsAg, Gastroenterology

WARMINSTER, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that clinical data for AB-729, an RNAi therapeutic, and preclinical data for AB-161, a next-generation oral HBV specific RNA destabilizer, were presented as late-breaker oral presentations at the Global Hepatitis Summit 2023 in Paris.

Key Points: 
  • The data show that AB-161 provides robust anti-HBV activity including suppression of HBV RNA and HBsAg production in vitro and in vivo.
  • Data from the mechanism of action studies show that AB-161 promotes viral transcript degradation and reduces viral proteins and viral replication.
  • Preclinical pharmacokinetic data and repeat dose toxicology studies show enhanced liver concentrations and lack of peripheral neuropathy.
  • We have recently initiated a Phase 1 clinical trial in healthy subjects and look forward to sharing the initial data in the second half of this year.”